BioMarin’s Hemophilia Gene Therapy Still Works After Four Years, But Effects Tail Off

FDA Approval Expected By Late 2020

 
• By Andrew McConaghie
  
Biomarin
BioMarin expects to reach profitability in 2020, and a Roctavian approval would cap the year off
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Gene Therapies

More from Advanced Therapies